Xylitol Toxicity in Dogs: Treatment

Xylitol causes a rapid, insulin-mediated hypoglycemia in dogs (plasma insulin rose sharply within 20 minutes of experimental oral dosing and blood glucose began falling by 30 minutes). Ingestion can also trigger acute hepatic failure with coagulopathy, which killed or led to euthanasia in 5 of the 8 dogs in the case series that first described it. Management rests on early decontamination when appropriate, hospitalization with serial blood glucose monitoring, IV dextrose for hypoglycemia, and aggressive supportive care if hepatic injury develops. Prognosis is excellent for dogs that reach a veterinarian and do not develop liver failure: in the largest retrospective (192 dogs, three university teaching hospitals), 30 dogs became hypoglycemic (blood glucose ≤ 3.3 mmol/L [60 mg/dL]) at some point during hospitalization and 30 developed increased ALT activity or total bilirubin, yet every dog survived to discharge.

Mechanism

In dogs, xylitol is a strong promoter of insulin release and can cause severe hypoglycemia with ataxia, collapse, and seizures; in humans, xylitol has little to no effect on plasma insulin or glucose levels (Dunayer, 2004). The time course was characterized experimentally in 18 adult Pekingese dogs given 1 or 4 g/kg xylitol orally: plasma insulin rose sharply from 20 minutes after dosing and peaked at 40 minutes, and blood glucose started to decrease 30 minutes after dosing (Xia et al., 2009). That experimental study also documented increased ALT and AST activities, hypophosphatemia, hypokalemia, and hypercalcemia, with sodium and chloride remaining normal. Hepatic injury is the second phase: in the 2006 JAVMA series, all 8 dogs were evaluated for lethargy and vomiting after xylitol ingestion, and 5 of the 8 had widespread petechial, ecchymotic, or gastrointestinal tract hemorrhages, moderately to severely high liver enzyme activities, hyperbilirubinemia, hypoglycemia, hyperphosphatemia, prolonged clotting times, and thrombocytopenia; necropsy of 3 dogs showed severe hepatic necrosis in 2 and severe hepatocyte loss or atrophy with lobular collapse in the third (Dunayer & Gwaltney-Brant, 2006). In one well-documented case, hypoglycemia developed within 1-2 hours of ingestion, elevated liver values within 12 hours, and coagulopathy in less than 24 hours (Schmid & Hovda, 2016).

Study details

• Retrospective, 192 client-owned dogs (2007-2012), three university teaching hospitals (DuHadway et al., 2015): median ingested xylitol dose 0.32 g/kg (range 0.03-3.64 g/kg); clinical signs on presentation in 39 dogs (20%), most commonly vomiting (25) then lethargy (12); dogs that developed clinical signs had ingested a significantly higher dose than asymptomatic dogs.
• Retrospective, 95 dogs (2018-2022), one university teaching hospital and one private-practice emergency hospital (Lovell et al., 2025): evaluated patient history, clinical signs, decontamination methods (emesis induction, activated charcoal), and point-of-care diagnostics (PCV/total plasma protein, lactate, blood glucose, potassium) against development of hepatopathy.
• Case series, 8 adult dogs (Dunayer & Gwaltney-Brant, 2006): the first report of acute hepatic failure and coagulopathy associated with xylitol ingestion.
• Experimental study, 18 adult clinically normal Pekingese dogs dosed with 1 or 4 g/kg xylitol in aqueous solution (Xia et al., 2009): characterized insulin and glucose time course and plasma biochemistry.
• Case reports: a 9-month-old neutered male Labrador Retriever with severe hypoglycemia, collapse, and seizures after xylitol-sweetened gum (Dunayer, 2004); and a 9-year-old 4.95 kg neutered male Chihuahua that ingested 224 g (45 g/kg) granulated xylitol and survived with aggressive care (Schmid & Hovda, 2016).

Decontamination

In the 95-dog retrospective, emesis was induced in 77% of dogs, and dogs in which emesis was induced were less likely to develop a hepatopathy than dogs in which it was not (p = 0.01). Dogs with clinical signs prior to presentation were 1.95 times more likely to develop a hepatopathy (p = 0.0005), and hypokalemia on presentation was associated with hepatopathy development (p = 0.0353). Notably, the ingested dose was not associated with hepatopathy in this cohort, and no dog developed evidence of hepatic failure.

Monitoring

Dogs ingesting xylitol should be hospitalized and monitored for variations in blood glucose, because BG drops in most dogs following presentation: in the 192-dog retrospective, 30 dogs became hypoglycemic (≤ 3.3 mmol/L [60 mg/dL]) at some time point during hospitalization, there was a significant difference between initial and lowest blood glucose values across all dogs, and the 30 dogs with increased ALT activity or total serum bilirubin had a significantly lower glucose nadir. Liver values warrant the same vigilance: 30 of the 192 dogs had increased ALT activity or total serum bilirubin. When hepatic injury is suspected, add coagulation times and platelet counts, which were prolonged and decreased in the hepatic-failure series, plus bilirubin, phosphorus, potassium, and calcium (all reported as deranged in at least one of the series or the experimental study).

Treatment of hypoglycemia and hepatic failure

For hypoglycemia, the verified mainstay is IV dextrose: the original case report was treated with IV dextrose boluses plus a continuous infusion, improved rapidly, and remained mildly hypoglycemic for 11 hours before recovering fully (Dunayer, 2004). For dogs that progress to hepatic failure and coagulopathy, reported care includes IV fluids, plasma transfusions, and dextrose as indicated (Dunayer & Gwaltney-Brant, 2006). In the surviving 45 g/kg case, treatment comprised maropitant, intravenous dextrose, phytonadione, metronidazole, and fresh frozen plasma, with N-acetylcysteine (NAC) and S-adenosyl-L-methionine (SAMe) providing hepatic detoxification and support; liver values returned to normal within 1 month, and no adverse effects on hepatic function were identified 2 years later (Schmid & Hovda, 2016).

None of the cited abstracts report dose thresholds, drug doses, or monitoring intervals, so this page states none. For those, consult a current formulary or the ASPCA Animal Poison Control Center.

Prognosis

The prognosis for dogs evaluated by a veterinarian that ingest lower doses of xylitol and do not develop liver failure is excellent: all 192 dogs in the multicenter retrospective survived to discharge, and 158 were known to be alive at 28 days (the remainder lost to follow-up). A 2018 review concludes that prognosis is generally expected to be good for dogs developing uncomplicated hypoglycemia (Murphy & Dunayer, 2018), and in the 95-dog 2025 retrospective no dog developed evidence of hepatic failure. Once acute hepatic failure with coagulopathy develops, outcomes are guarded: 5 of 8 dogs in the 2006 series died or were euthanized (2 made complete recoveries; 1 was recovering but lost to follow-up). Survival is nevertheless possible even after massive ingestion: the 45 g/kg case survived with liver values normal at 1 month and no adverse hepatic effects identified 2 years after ingestion (Schmid & Hovda, 2016).

Clinical context and limitations

All population-level evidence is retrospective and reflects dogs presented to veterinary hospitals; dogs that die before presentation are not captured. Dose-response remains unresolved: the 2015 retrospective found that dogs with clinical signs had ingested significantly higher doses but concluded that additional studies are needed before correlations between dose and the development of clinical signs or liver failure can be established, and the 2025 retrospective found ingested dose was not associated with hepatopathy. The emesis finding is an association, not proof of causation, and may partly reflect presentation timing or other confounders. The experimental study used Pekingese dogs dosed with xylitol in aqueous solution rather than commercial products, so kinetics may differ by breed and product. “Hepatopathy” definitions and the hypoglycemia cutoff (≤ 3.3 mmol/L [60 mg/dL]) are study-specific operational definitions, and the 2006 case series predates modern hepatoprotectant use.

Ask Vetinuity

For follow-up questions about decontamination, dextrose and hepatoprotectant use, or monitoring after xylitol ingestion, ask the Vetinuity clinical assistant.